Oppenheimer increased its price target for Dianthus Therapeutics (NASDAQ:DNTH) to $125.00 from $62.00 and maintained an Outperform rating on the shares. The new target stands above the prevailing analyst high of $100, while the stock was trading at $50.50, according to InvestingPro data.
The research house pointed to several drivers behind its more bullish view. Dianthus stock has advanced 22% year-to-date, outperforming the XBI biotech index, which has gained 5% over the same period. The firm linked part of the move to remarks by CEO Marino Garcia at the company’s January annual healthcare conference, where he discussed potential superiority versus competitor complement inhibitors and shared expectations around pricing.
InvestingPro data cited by the research firm underscores the company’s recent momentum: a 142% total return over the past year and a 136% gain over the last six months.
Oppenheimer identified a sequence of near-term clinical milestones it views as material to valuation and investor sentiment. Those include a mid-year update on the Phase 3 interim analysis for claseprubart in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), followed by Phase 2 data in multifocal motor neuropathy (MMN) and initial DNTH212 results from healthy volunteer testing slated for the second half of 2026.
The analyst noted that market pricing appears to assign limited value today to the DNTH212 program and the MMN indication despite the recent appreciation in shares after multiple sclerosis data.
Oppenheimer suggested that Dianthus could be at an early stage of potential revaluation - a view that depends on rising investor confidence in the company’s CIDP and MMN profiles and on increased clarity about DNTH212’s characteristics as clinical data roll out.
Separately, Dianthus announced the dosing of the first subject in a Phase 1 study of LBL-047, a bifunctional fusion protein designed to treat autoimmune disorders. The trial, conducted in collaboration with Leads Biolabs, will examine safety and efficacy in both healthy volunteers and patients with systemic lupus erythematosus (SLE).
In addition to Oppenheimer’s move, H.C. Wainwright increased its price target for Dianthus to $47 from $40 while keeping a Buy rating. That adjustment followed positive Phase 2 topline results for claseprubart in myasthenia gravis and further data from an open-label extension study.
Context and implications
- Analyst actions and clinical milestones are central to near-term sentiment and valuation for the company.
- The biotech and broader healthcare sectors are directly implicated by these updates, and market reaction has influenced share performance versus biotech benchmarks.
- Investor reassessment appears linked to both recent trial data and management commentary on product positioning and pricing.